IPO
IPO filing, visualized

CITY THERAPEUTICS, INC.

CTY · Nasdaq424B4 · Oct 16, 2026Priced Oct 15, 2026

Priced Oct 15, 2026 · range was $17–$19 · latest SEC filing Nov 10, 2026.

Pinch-zoom for details.

The offering

Final price
$18.00
per share, from the final prospectus
Shares offered
11.1M
+1.67M over-allotment option
Raise at the final price
$200M
11,111,111 × $18, before fees

What the company does

Clinical-stage biotech developing RNA-interference (RNAi) medicines that switch off disease-related proteins.

Revenue

Fiscal year

1st half

Operating result

Fiscal year

1st half

Net result

Fiscal year

1st half

Things to weigh

  • Loss-making: net loss of $53.4M in H1 2026.

The numbers

$FY2024FY2025YoYH1 2025H1 2026Change
Revenue2.78M13.6M+388%5.58M6.36M+14.0%
Operating result(29.1M)(59.9M)−106%(26.6M)(51.1M)−92.3%
Net result(27.8M)(58.5M)−110%(24.3M)(53.4M)−120%
$FY2024FY2025YoY
Revenue2.78M13.6M+388%
Operating result(29.1M)(59.9M)−106%
Net result(27.8M)(58.5M)−110%
$H1 2025H1 2026Change
Revenue5.58M6.36M+14.0%
Operating result(26.6M)(51.1M)−92.3%
Net result(24.3M)(53.4M)−120%

Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.

Risks

The filing doesn't set out its risks in a list we could read.

Strategy

  1. Pioneer the future of RNAi trigger design and delivery
  2. Advance development candidates in high unmet medical need indications where RNAi offers meaningful advantages
  3. Selectively pursue value-accretive partnerships to maximize the value of our portfolio
  4. Bring exceptional depth of experience to accelerate and expand our pipeline

The filing's own strategy headings, shortened.

Source: CITY THERAPEUTICS, INC.'s Form 424B4, filed with the SEC on Oct 16, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.